Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials

BACKGROUND: Studies testing the addition of lapatinib to neoadjuvant trastuzumab + chemotherapy reported an increase in pathologic complete response (pCR), with, nevertheless, discordant results in terms of survival, mainly due to suboptimal power. We here leverage the meta-analytic approach to reso...

Descripción completa

Detalles Bibliográficos
Autores principales: Guarneri, V., Griguolo, G., Miglietta, F., Conte, P.F., Dieci, M.V., Girardi, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917305/
https://www.ncbi.nlm.nih.gov/pubmed/35276440
http://dx.doi.org/10.1016/j.esmoop.2022.100433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917305/
https://www.ncbi.nlm.nih.gov/pubmed/35276440
http://dx.doi.org/10.1016/j.esmoop.2022.100433

Ejemplares similares